BOSTON, May 23, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab ...Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Verastem Oncology's investigational RAF/MEK clamp, avutometinib, in combination with Amgen's KRAS G12C inhibitor, LUMAKRAS TM (sotorasib), for the treatment of patients ...Mizuho Securities analyst Graig Suvannavejh maintained a Buy rating on Verastem (VSTM Research Report) on March 25 and set a price target of $36... Verastem (VSTM, $11.53) price exceeded its 50-day Moving Average on March 25, 2024 Tickeron - Technical Analysis • about 2 months ago. This price move could indicate a change in the trend, and may ...Track VERSES Technologies Inc - Ordinary Shares - Class A (Sub Voting) (VRSSF) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVSTM Competitors. $ Market cap P/E ratio $ Price 1d change 52-week range. View Verastem, Inc. VSTM stock quote prices, financial information, real-time forecasts, and company news from CNN.The forward-looking statements contained in this press release reflect Verastem Oncology's views as of the date hereof, and Verastem Oncology does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.Discover Verastem Inc (VSTM) market and community sentiment, movement in message volume, participation score and buzz level in the Stocktwits communitySummary. Verastem Oncology (NASDAQ:VSTM) is an early-stage biotechnology company developing new medicines for cancer patients.The company was founded in 2010 originally to develop new drugs ...Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival ...Registration-Directed RAMP-201 Trial Designed to Address High Unmet Need in Low-Grade Serous Ovarian Cancer, a Unique and Distinct Type of Ovarian Cancer with Limited Treatment Options . BOSTON--(BUSINESS WIRE)--Apr. 26, 2023-- Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that an abstract ...This air purifier removes dust, pollen, smoke, pet dander, and more — and right now, it’s $70 off! By clicking "TRY IT", I agree to receive newsletters and promotions from Money an...Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote …Track Amesite Inc (AMST) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsCompany ended Q3 2023 with $21.3 million GAAP operating expenses and $19.8 million non-GAAP operating expenses* 3. * Q3 2023 GAAP operating expenses - $21.31M less Q3 2023 stock compensation of $1.52M = $19.79M Q3 2023 non-GAAP operating expenses.Track Visium Technologies Inc (VISM) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsFind the latest Verastem (VSTM) discussion and analysis from iHub's community of investors.TPG readers chimed in to tell us which brands of hotel soaps, shampoos, lotions and conditioners are their favorites. As a rule, the nicer the hotel, the less likely it is that you...Analysts Offer Insights on Healthcare Companies: Verastem (VSTM), ANI Pharmaceuticals (ANIP) and Argenx Se (ARGX) May 13, 2024TipRanks. RBC Capital Sticks to Their Buy Rating for Verastem (VSTM ...Verastem Inc News Alert. Email. Leave this field blank. Investor Contact. Julissa Viana. Investor Relations [email protected]. Ryan Porter. Argot Partners +1 212-600-1902 [email protected]. Investor Kit Corporate Presentation 1.8 MB. VSTM-Form-10-K-2023.pdf 1.7 MB.Andreas Halvorsen's Viking Global Investors LP Bolsters Position in Verastem Inc. The transaction, which took place on December 31, 2023, involved the acquisition of 75,537 shares at a trade price of $8.14 per share. This strategic move has expanded Viking Global's holding to a total of 2,531,829 shares in Verastem Inc, reflecting the firm's ...Mr Paterson joined Verastem Oncology in 2011 and was its President and Chief Operating Officer prior to becoming President and Chief Executive Officer in 2023. He has more than 30 years of experience at healthcare and biotechnology companies, including leadership roles as Chief Business Officer (CBO), Chief Operating Officer (COO) and Chief ...The detail page will show you the real-time trend, you can click into the MSN Money website for more detailsBOSTON, May 31, 2023--Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it will effect a 1-for-12 ...The stock options have an exercise price equal to $7.65 per share, the closing price of Verastem Oncology's common stock as reported by Nasdaq on October 12, 2023.At Syndax, we are advancing the next generation of targeted treatments to realize a future in which people with cancer live longer and better than ever before. We are a clinical stage oncology innovator developing first-in-class therapies for acute leukemias and chronic graft-versus-host disease. Our team is committed to adhering to scientific ...Verastem Oncology (Nasdaq: VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with cancer. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and ...Investors may trade in the Pre-Market (4:00-9:30 a.m. ET) and the After Hours Market (4:00-8:00 p.m. ET). Participation from Market Makers and ECNs is strictly voluntary and as a result, these ...BOSTON, January 18, 2024--Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug ...Stock analysis for Verastem Inc (VSTM:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Track Ginkgo Bioworks Holdings Inc - Ordinary Shares - Class A (DNA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsFintel reports that on June 27, 2023, Truist Securities reiterated coverage of Verastem ( NASDAQ:VSTM) with a Buy recommendation. Analyst Price Forecast Suggests 393.85% Upside. As of June 2, 2023 ...BOSTON, May 23, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab ...Verastem, Inc., operating as Verastem Oncology, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients.Price to Book. 11.61. Revenue Per Employee. N/A. Enterprise Value/EBITDA. -2.77. Get all financial information for Verastem Inc (VSTM) including Market Capitalization, PE Ratio, EBITDA, EPS, previous close and open price, 52 week high & 52 week low, Beta and much more.Track CAVA GROUP INC (CAVA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsTrack Palantir Technologies Inc (PLTR) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer. BOSTON-- (BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company committed to advancing new medicines for patients with cancer, announced today that it has ...This press release includes forward-looking statements about Verastem Oncology’s strategy, future plans and prospects, including statements related to the expected outcome and benefits of the collaboration with GenFleet, the potential clinical value of various of its clinical trials, the timing of commencing and completing trials, including ...Verastem Oncology (Nasdaq: VSTM) is a development-stage biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed ...Verastem Oncology is currently conducting clinical trials with its RAF/MEK clamp avutometinib in RAS pathway-driven tumors as part of its (Raf And Mek Program). RAMP 301 is a Phase 3 confirmatory ...Stocktwits provides real-time stock, crypto & international market data to keep you up-to-date. Find top news headlines, discover your next trade idea, share & gain insights from traders and investors from around the world, build a watchlist, buy US stocks, & create and manage your portfolio.BOSTON--(BUSINESS WIRE)--Jan. 18, 2023-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of 96,700 restricted stock units (RSUs) to four new employees.The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees' acceptance of ...Verastem Oncology is currently conducting clinical trials with its RAF/MEK clamp avutometinib in RAS pathway-driven tumors as part of its (Raf And Mek Program). RAMP 301 is a Phase 3 confirmatory ...Novel therapies and combinations are urgently needed to deliver on the promise of better outcomes for patients. Find out more about our clinical trials. At Verastem Oncology, we recognize and prioritize the importance of partnership with the research and patient advocacy communities to create and support approaches to better care.Registration-Directed RAMP-201 Trial Designed to Address High Unmet Need in Low-Grade Serous Ovarian Cancer, a Unique and Distinct Type of Ovarian Cancer with Limited Treatment Options . BOSTON--(BUSINESS WIRE)--Apr. 26, 2023-- Verastem Oncology, (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that an abstract ...Track VERSES Technologies Inc - Ordinary Shares - Class A (Sub Voting) (VRSSF) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019-)View the latest Verastem Inc. (VSTM) stock price, news, historical charts, analyst ratings and financial information from WSJ.www.verastem.com. Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase ...Free VSTM Stock Alerts. $11.50. -0.63 (-5.19%) (As of 05/17/2024 08:54 PM ET) Compare. Share. Stock Analysis Analyst Forecasts Chart Competitors Earnings Financials Headlines Insider Trades Options Chain Ownership SEC Filings Short Interest Social Media. Media Mentions Over Time. 10.Credit: Kateryna Kon / Shutterstock.com. The US Food and Drug Administration (FDA) has granted fast track designation for Verastem Oncology's investigational therapy, avutometinib, for treating non-small cell lung cancer (NSCLC). The FDA designation is intended for the use of avutometinib along with Amgen 's LUMAKRAS (sotorasib) to treat ...Stocktwits is the leading social platform for investors and traders to share ideas, insights and opinions about the stock, crypto and international markets. Join the Stocktwits community, follow your favorite symbols, get real-time quotes, news, earnings and fundamentals, and buy US stocks with ease.Track Marathon Digital Holdings Inc (MARA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsRing Energy, Inc. analysts consensus, targets, ratings and recommendations | Nyse: REI | NyseVerastem (VSTM) avutometinib in combination with Amgen's Lumakras has received FDA fast track status in the treatment of a certain type of lung cancer. Read more here.Earnings Per Share - Diluted of $2.29; Earnings Per Share - Diluted, as Adjusted, of $6.86Total Sales of $7.9B; Net Flows of ($4.8B); Assets Under... HARTFORD, Conn., July 29, 2022...Verastem Oncology is also supporting an investigator-initiated Phase 2 trial evaluating VS-6766 with defactinib in patients with metastatic uveal melanoma. Verastem Oncology has initiated Phase 2 registration-directed trials of VS-6766 with defactinib in patients with recurrent LGSOC and in patients with recurrent KRAS-G12V mutant …Get the latest Verastem Inc (VSTM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Need a Facebook advertising agency in Canada? Read reviews & compare projects by leading Facebook marketing companies. Find a company today! Development Most Popular Emerging Tech ...Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. Verastem, Inc. Common Stock (VSTM) Pre-Market Stock Quotes - Nasdaq offers pre ...BOSTON--(BUSINESS WIRE)--Jan. 24, 2023-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that it has entered into a definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock (the “Preferred Stock”) to affiliates of BVF Partners L.P. in a private ...See the latest Verastem Inc stock price (VSTM:XNAS), related news, valuation, dividends and more to help you make your investing decisions.The following organizations are good resources for information on colorectal cancer: The following organizations are good resources for information on colorectal cancer: Resources ...Inside Verastem, Inc.'s 10-K Annual Report: Other - Other Highlight. For example, if the FDA or other regulatory authority were to require us to conduct clinical trials beyond those which we currently anticipate will be required for the completion of clinical development of a product candidate or if we experience significant delays in enrollment in any clinical trials, we could be required to ...Track Viasat, Inc. (VSAT) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsVerastem Inc News Alert. Email. Leave this field blank. Investor Contact. Julissa Viana. Investor Relations [email protected]. Ryan Porter. Argot Partners +1 212-600-1902 [email protected]. Investor Kit Corporate Presentation 1.8 MB. VSTM-Form-10-K-2023.pdf 1.7 MB.Verastem, Inc. Common Stock (VSTM) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.BOSTON--(BUSINESS WIRE)--Apr. 4, 2024-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 35,000 shares of its common stock to four new employees.The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employees ...Track Geron Corp. (GERN) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsBOSTON, March 14, 2024--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today reported financial results for the three ...Get the latest Syros Pharmaceuticals Inc (SYRS) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle ...Verastem stock resides in the small cap universe with a market cap of $263M and a share price of $10.43 which is closing in on its 52-week high share price of $15.12. Over the past year, the stock ...Verastem Oncology is an American pharmaceutical company that develops medicines to treat certain cancers. Headquartered and founded in Boston, Massachusetts, the firm is a member of NASDAQ Biotechnology Index. Wikipedia. Headquarters: Massachusetts. Founded: 2010. CEO: Brian Stuglik (Jul 2019–)VSTM on Twitter. Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The company's lead FAK inhibitor, VS-6063, is in Phase I/Ib ...Verastem Trading Down 4.3 %. VSTM stock opened at $11.30 on Monday. The company has a market capitalization of $285.83 million, a PE ratio of -2.76 and a beta of 0.48. Verastem has a 12 month low ...EPS. -$4.40. Price to Book. 11.61. Revenue Per Employee. N/A. Enterprise Value/EBITDA. -2.77. Get all financial information for Verastem Inc (VSTM) including Market Capitalization, PE Ratio, EBITDA, EPS, previous close and open price, 52 week high & 52 week low, Beta and much more.BOSTON--(BUSINESS WIRE)--Jan. 18, 2024-- Verastem Oncology (Nasdaq:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to Verastem Oncology’s investigational RAF/MEK …Get the latest Verastem Inc (VSTM) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.. DVAXDynavax Technologies Corporation. 11.88. +3.66%. FiLearn more. Track Root Inc (ROOT) Stock Price, Quote, latest Verastem Oncology (Nasdaq: VSTM) is a late-stage development biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients ...Economist Nouriel Roubini said Credit Suisse needs a liquidity lifeline from central banks — and the Swiss National Bank just agreed a $54 billion loan. Jump to Credit Suisse could... GFH375/VS-7375. GFH375/VS-7375 is an orally According to 4 analyst offering 12-month price targets in the last 3 months, Verastem has an average price target of $28.0 with a high of $36.00 and a low of $21.00. Shares of Verastem, Inc. (NASDAQ:VSTM – Get Free Report) have been ...
Continue Reading